NASDAQ: CLOVClover Health Investments Corp Stock
$2.66+0.07 (+2.7%)
Updated Dec 10, 2025
CLOV Price
$2.66
Fair Value Price
N/A
Market Cap
$1.37B
52 Week Low
$2.12
52 Week High
$4.87
P/E
-24.18x
P/B
4.03x
P/S
0.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.77B
Earnings
-$58.32M
Gross Margin
21.2%
Operating Margin
-3.29%
Profit Margin
-3.3%
Debt to Equity
0.64
Operating Cash Flow
-$85M
Beta
1.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CLOV Overview
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLOV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
B
CLOV
Ranked#9 of 10
Ranked#9 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $262.60 | B | |
| $18.91 | B | |
| $341.04 | B |
Be the first to know about important CLOV news, forecast changes, insider trades & much more!
CLOV News
Overview
Due Diligence Score
–
Industry Average (38)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLOV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLOV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLOV is poor value based on its book value relative to its share price (4.03x), compared to the US Healthcare Plans industry average (2.04x)
P/B vs Industry Valuation
CLOV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CLOV due diligence checks available for Premium users.
Valuation
CLOV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24.18x
Industry
43.73x
Market
46.23x
CLOV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.03x
Industry
2.04x
CLOV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLOV's financial health
Profit margin
Revenue
$496.7M
Net Income
-$24.4M
Profit Margin
-4.9%
CLOV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CLOV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$559.7M
Liabilities
$218.7M
Debt to equity
0.64
CLOV's short-term assets ($330.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLOV's short-term assets ($330.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLOV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLOV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.1M
Investing
-$5.4M
Financing
-$5.3M
CLOV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLOV vs Healthcare Plan Stocks
Clover Health Investments Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.